Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1477243

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1477243

Diabetic Kidney Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 162 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Global diabetic kidney disease market is estimated to be valued at USD 3.03 Bn in 2024 and is expected to reach USD 4.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 3.03 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 4.80% 2031 Value Projection: US$ 4.21 Bn
Figure 1. Diabetic Kidney Disease Market Share (%), By Region, 2024
Diabetic Kidney Disease Market - IMG1

Diabetic kidney disease (DKD) is a condition in which the kidneys are damaged due to long-standing diabetes. Over time, high blood sugar from diabetes can damage both the small blood vessels in the kidneys as well as the filtering units (glomeruli) within the kidneys. Damage to the glomeruli can reduce kidney function and may lead to kidney failure, if not controlled effectively. With increasing prevalence of diabetes globally, the market for treatments of diabetic kidney disease is projected to grow steadily in the near future.

Market Dynamics:

Global diabetic kidney disease market is witnessing significant growth due to rising prevalence of diabetes and obesity worldwide. Some of the key drivers fueling the market growth include growing geriatric population who are more susceptible to chronic kidney diseases, rising awareness about early diagnosis and treatment of DKD, and increasing U.S. FDA approvals of novel drugs to treat DKD. However, factors such as high costs associated with kidney failure treatments and lack of diseases awareness in low-income regions can hamper the market growth. Ongoing R&D efforts to develop more efficacious drugs with improved safety profiles provide lucrative opportunities for market players. Increasing health expenditures of governments worldwide on kidney care is anticipated to create a positive business environment during the forecast period.

Key Features of the Study:

  • This report provides in-depth analysis of the global diabetic kidney disease market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global diabetic kidney disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study includes AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, and Vertex Pharmaceuticals Incorporated.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global diabetic kidney disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic kidney disease market.

Detailed Segmentation-

  • Drug Class:
    • Angiotensin Receptor Blockers (ARBs)
    • Calcium Channel Blockers
    • Antioxidant Inflammation Modulator
    • Angiotensin-Converting Enzyme (ACE) Inhibitors
    • Others
  • Route of Administration:
    • Oral
    • Parenteral
  • Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • Boehringer Ingelheim
    • Janssen Pharmaceuticals
    • Bristol Myers Squibb
    • GSK
    • Novo Nordisk
    • Eli Lilly and Company
    • Merck & Co.
    • Sanofi
    • AbbVie
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd
    • Lupin
    • Aurobindo Pharma
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Vertex Pharmaceuticals Incorporated
Product Code: CMI6852

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Technology Overview
  • Regulatory Scenario
  • Pricing Analysis
  • PEST Analysis

4. Global Diabetic Kidney Disease Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Diabetic Kidney Disease Market, By Drug Class, 2019 - 2031, (USD BN)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Angiotensin Receptor Blockers (ARBs)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Calcium Channel Blockers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Antioxidant Inflammation Modulator
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Diabetic Kidney Disease Market, By Route of Administration, 2019 - 2031, (USD BN)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Diabetic Kidney Disease Market, By Distribution Channel, 2019 - 2031, (USD BN)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Diabetic Kidney Disease Market, By Region, 2019 - 2031, (USD BN)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Boehringer Ingelheim
    • Janssen Pharmaceuticals
    • Bristol Myers Squibb
    • GSK
    • Novo Nordisk
    • Eli Lilly and Company
    • Merck & Co.
    • Sanofi
    • AbbVie
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd
    • Lupin
    • Aurobindo Pharma
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Vertex Pharmaceuticals Incorporated

10. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!